Navigation Links
Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Date:1/4/2008

ed Mr. Sekhri. "We are extremely pleased to have Matt join us as a member of our senior management team and believe he will contribute greatly to our efforts of building a pipeline of products aligned with our corporate strategy."

About Cerimon Pharmaceuticals

Cerimon Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for autoimmune diseases, inflammation, and pain. Cerimon believes these new treatment options will enable physicians specialized in treating these conditions to further improve the lives of their patients.

Cerimon currently has two drugs in development. Simulect(R) (basiliximab) entered a Phase IIb study for moderate-to-severe ulcerative colitis in the first quarter of 2007. Cerimon's topical patch formulation of diclofenac sodium completed a Phase I study in the fourth quarter of 2007. This study will rapidly be followed by two Phase II/III studies for the treatment of acute musculoskeletal pain.

The Company is well-financed, having closed a $70 million Series A financing in late 2005 with premier investors including MPM, Nomura Phase4 Ventures, and OrbiMed Advisors.

For more information on Cerimon, please visit the Company's website at http://www.cerimon.com.


'/>"/>
SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cerimon Pharmaceuticals to Present at the 2007 BIO Investor Forum
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... November 23, 2014 Apiscent Labs, ... of fine chemical ingredients to the global pharmaceutical ... of its new website, Apiscent.com. , The Apiscent.com ... Labs, clean design, easy navigation, rotating images and ... Labs stand out. , The company’s ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 During his ... understood the need to surround himself with great people ... and entrepreneur, his friends often marveled at his extraordinarily ... lived his life and -- even with his death ... the Alzheimer’s disease that would ultimately take his life. ...
(Date:11/22/2014)... Denver, Colo. (PRWEB) November 21, 2014 ... of proprietary cloud based analytics and scientific testing methodologies ... a commitment for a $750,000 line of credit from ... are extremely pleased to have secured this commitment from ... Chief Executive Officer of CannLabs. “This capital will help ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 On November ... at the 2014 Emerging Medical Technologies Summit in San ... Awards. Widely regarded among Silicon Valley investors and ... device innovation, the win also positions Briteseed to ... Innovator competition in 2015 and compete with other elite ...
Breaking Biology Technology:Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3CannLabs Secures $750,000 Line Of Credit 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3
... /Xinhua-PRNewswire-FirstCall/ --,China Biologic Products, Inc. (OTC Bulletin ... of the leading plasma-based pharmaceutical companies,in the ... announced that on,August 6, 2008, the PRC,s ... China Biologic,s production facility in Taian City ...
... Sinovac Biotech Ltd. (Amex:,SVA), a leading provider of vaccines ... scheduled for September 4, 2008 has been,adjourned to September ... General Meeting, the required quorum of,a majority of the ... the meeting is adjourned to September 18, 2008 (the ...
... PHILADELPHIA and LONDON, Sept. 4 Thomson ... for businesses and,professionals, announced today that the ... of scientists worldwide using BIOMARKERcenter, the,first comprehensive ... diagnostic, and research organizations with,a framework for ...
Cached Biology Technology:China Biologic's Production Facility Renews GMP Certification 2China Biologic's Production Facility Renews GMP Certification 3Sinovac Adjourns Annual General Meeting 2The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters 2The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters 3
(Date:11/4/2014)... marketing directed at children on the interior and ... the majority of black, middle-income and rural communities ... Authored by Arizona State University researcher Punam Ohri-Vachaspati ... to examine the use of child-directed marketing on ... and its relationship to demographics. It adds to ...
(Date:11/4/2014)...   Neurotechnology , a provider of high-precision ... version of its fingerprint matching algorithm has achieved ... evaluation organized by NIST. The MINEX test measures ... 378 fingerprint standard template format. MINEX compliance is ... the United States and ...
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® , ... life sciences company focused on commercialization of its ... for the treatment of neurological and neuropsychiatric disorders, ... Property has issued a Notice of Allowance for ... is co-owned by NeuroSigma and the Regents of ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... Ariz. and ROSEMONT, Ill. September 12, 2013 ... today announced that the Pac-12,s Arizona State University and ... first university research partner in a new study designed ... groundbreaking joint research project is the first of its ...
... softballs, both approved for league play, can have dramatically different ... findings from a study conducted by Professor Lloyd Smith in ... Derek Nevins that they will present at the Asia Pacific ... Their work was published in the journal, Procedia Engineering ...
... Sept. 12, 2013 Taking a page from ... Research Institute (TGen) today initiated the first-in-human clinical trial ... a plant known as "Thunder God vine." ... received treatment today at Scottsdale Healthcare,s Virginia G. Piper ...
Cached Biology News:ASU football program is first collegiate partner in TGen-Riddell concussion detection study 2ASU football program is first collegiate partner in TGen-Riddell concussion detection study 3ASU football program is first collegiate partner in TGen-Riddell concussion detection study 4Researchers hit virtual heads to make safer games 2TGen and Scottsdale Healthcare launch Phase I 'Thunder God vine' trial for cancer 2TGen and Scottsdale Healthcare launch Phase I 'Thunder God vine' trial for cancer 3
... Kits provide rapid and efficient removal of ... and salts from PCR products (Figure 1). ... two Binding Buffer options for fragments >100 ... performed in either single column or 96-well ...
...
Immunogen: Recombinant full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Biology Products: